دورية أكاديمية
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
| العنوان: | Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. |
|---|---|
| المؤلفون: | Taylor DC; i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA. douglas.taylor@i3innovus.com, Pandya A, Thompson D, Chu P, Graff J, Shepherd J, Wenger N, Greten H, Carmena R, Drummond M, Weinstein MC |
| المصدر: | The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2009 Jul; Vol. 10 (3), pp. 255-65. Date of Electronic Publication: 2008 Sep 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1618-7598 (Print) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag, c2001- |
| مواضيع طبية MeSH: | Anticholesteremic Agents/*economics , Anticholesteremic Agents/*therapeutic use , Cardiovascular Diseases/*drug therapy , Cardiovascular Diseases/*prevention & control , Heptanoic Acids/*economics , Heptanoic Acids/*therapeutic use , Pyrroles/*economics , Pyrroles/*therapeutic use, Anticholesteremic Agents/administration & dosage ; Atorvastatin ; Cost-Benefit Analysis ; Dose-Response Relationship, Drug ; Europe ; Heptanoic Acids/administration & dosage ; Humans ; Markov Chains ; Pyrroles/administration & dosage ; Quality-Adjusted Life Years |
| مستخلص: | The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to 10 mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding costs of care, when compared to the A10 treatment, in all three countries. The incremental cost per QALY gained was |
| المشرفين على المادة: | 0 (Anticholesteremic Agents) 0 (Heptanoic Acids) 0 (Pyrroles) A0JWA85V8F (Atorvastatin) |
| تواريخ الأحداث: | Date Created: 20080919 Date Completed: 20090825 Latest Revision: 20181201 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s10198-008-0126-1 |
| PMID: | 18800232 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1618-7598 |
|---|---|
| DOI: | 10.1007/s10198-008-0126-1 |